161 related articles for article (PubMed ID: 16192597)
21. Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a phase II study from the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group.
Leahy M; Ray-Coquard I; Verweij J; Le Cesne A; Duffaud F; Hogendoorn PC; Fowst C; de Balincourt C; di Paola ED; van Glabbeke M; Judson I; Blay JY;
Eur J Cancer; 2007 Jan; 43(2):308-15. PubMed ID: 17095209
[TBL] [Abstract][Full Text] [Related]
22. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
23. Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial.
Stickeler E; Klar M; Watermann D; Geibel A; Földi M; Hasenburg A; Gitsch G
Breast Cancer Res Treat; 2009 Oct; 117(3):591-8. PubMed ID: 19156515
[TBL] [Abstract][Full Text] [Related]
24. Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
Chia S; Clemons M; Martin LA; Rodgers A; Gelmon K; Pond GR; Panasci L
J Clin Oncol; 2006 Jun; 24(18):2773-8. PubMed ID: 16682726
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of escalating doses of edatrexate in combination with paclitaxel in patients with metastatic breast cancer.
D'Andrea G; Fennelly D; Norton L; Baselga J; Gilewski T; Hudis C; Moynahan ME; Raptis G; Sklarin N; Surbone A; Theodoulou M; Templeton MA; Yao TJ; Seidman AD
Clin Cancer Res; 1999 Feb; 5(2):275-9. PubMed ID: 10037175
[TBL] [Abstract][Full Text] [Related]
26. Phase 2 trial of a novel capecitabine dosing schedule in combination with bevacizumab for patients with metastatic breast cancer.
Gajria D; Feigin K; Tan LK; Patil S; Geneus S; Theodoulou M; Norton L; Hudis CA; Traina TA
Cancer; 2011 Sep; 117(18):4125-31. PubMed ID: 21387266
[TBL] [Abstract][Full Text] [Related]
27. The sequential administration of combined doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Frassineti GL; Zoli W; Tienghi A; Ravaioli A; Milandri C; Gentile A; Salzano E; Amadori D
Semin Oncol; 1996 Oct; 23(5 Suppl 12):22-8. PubMed ID: 8941407
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas.
Maurel J; López-Pousa A; de Las Peñas R; Fra J; Martín J; Cruz J; Casado A; Poveda A; Martínez-Trufero J; Balañá C; Gómez MA; Cubedo R; Gallego O; Rubio-Viqueira B; Rubió J; Andrés R; Sevilla I; de la Cruz JJ; Del Muro XG; Buesa JM
J Clin Oncol; 2009 Apr; 27(11):1893-8. PubMed ID: 19273704
[TBL] [Abstract][Full Text] [Related]
29. Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre.
Bontenbal M; Creemers GJ; Braun HJ; de Boer AC; Janssen JT; Leys RB; Ruit JB; Goey SH; van der Velden PC; Kerkhofs LG; Schothorst KL; Schmitz PI; Bokma HJ; Verweij J; Seynaeve C;
J Clin Oncol; 2005 Oct; 23(28):7081-8. PubMed ID: 16192591
[TBL] [Abstract][Full Text] [Related]
30. Carboplatin/pemetrexed/bevacizumab in the treatment of patients with advanced non-small-cell lung cancer: a single-institution experience.
Malhotra B; Evans T; Weiss J; Eaby B; Stonehouse-Lee S; Sherry V; Langer CJ
Clin Lung Cancer; 2010 May; 11(3):192-7. PubMed ID: 20439196
[TBL] [Abstract][Full Text] [Related]
31. Multicenter randomized trial comparing sequential with concomitant administration of doxorubicin and docetaxel as first-line treatment of metastatic breast cancer: a Spanish Breast Cancer Research Group (GEICAM-9903) phase III study.
Alba E; Martín M; Ramos M; Adrover E; Balil A; Jara C; Barnadas A; Fernández-Aramburo A; Sánchez-Rovira P; Amenedo M; Casado A;
J Clin Oncol; 2004 Jul; 22(13):2587-93. PubMed ID: 15226326
[TBL] [Abstract][Full Text] [Related]
32. Brostallicin versus doxorubicin as first-line chemotherapy in patients with advanced or metastatic soft tissue sarcoma: an European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group randomised phase II and pharmacogenetic study.
Gelderblom H; Blay JY; Seddon BM; Leahy M; Ray-Coquard I; Sleijfer S; Kerst JM; Rutkowski P; Bauer S; Ouali M; Marreaud S; van der Straaten RJ; Guchelaar HJ; Weitman SD; Hogendoorn PC; Hohenberger P
Eur J Cancer; 2014 Jan; 50(2):388-96. PubMed ID: 24215845
[TBL] [Abstract][Full Text] [Related]
33. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
34. Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial.
De Maio E; Pacilio C; Gravina A; Morabito A; Di Rella F; Labonia V; Landi G; Nuzzo F; Rossi E; Silvestro P; Botti G; Di Bonito M; Curcio MP; Formichelli F; La Vecchia F; Staiano M; Maurea N; D'Aiuto G; D'Aiuto M; Thomas R; Signoriello G; Perrone F; de Matteis A
BMC Cancer; 2007 Mar; 7():50. PubMed ID: 17374151
[TBL] [Abstract][Full Text] [Related]
35. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
36. Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.
Burris H; Yardley D; Jones S; Houston G; Broome C; Thompson D; Greco FA; White M; Hainsworth J
J Clin Oncol; 2004 May; 22(9):1621-9. PubMed ID: 15117984
[TBL] [Abstract][Full Text] [Related]
37. Long-term response to pegylated liposomal doxorubicin in patients with metastatic soft tissue sarcomas.
Grenader T; Goldberg A; Hadas-Halperin I; Gabizon A
Anticancer Drugs; 2009 Jan; 20(1):15-20. PubMed ID: 19342997
[TBL] [Abstract][Full Text] [Related]
38. Bevacizumab in combination with oxaliplatin and doxorubicin or liposomal doxorubicin for hepatocellular cancer: a case series.
Ku GY; De Lima Lopes G; Chang AY
Asia Pac J Clin Oncol; 2011 Jun; 7(2):174-9. PubMed ID: 21585698
[TBL] [Abstract][Full Text] [Related]
39. Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model.
Chugh R; Griffith KA; Davis EJ; Thomas DG; Zavala JD; Metko G; Brockstein B; Undevia SD; Stadler WM; Schuetze SM
Ann Oncol; 2015 Jul; 26(7):1459-64. PubMed ID: 25858498
[TBL] [Abstract][Full Text] [Related]
40. First-Line Aldoxorubicin vs Doxorubicin in Metastatic or Locally Advanced Unresectable Soft-Tissue Sarcoma: A Phase 2b Randomized Clinical Trial.
Chawla SP; Papai Z; Mukhametshina G; Sankhala K; Vasylyev L; Fedenko A; Khamly K; Ganjoo K; Nagarkar R; Wieland S; Levitt DJ
JAMA Oncol; 2015 Dec; 1(9):1272-80. PubMed ID: 26378637
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
